GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of week 16 check-in — 46kg down, early fullness manageable, one thing confusing me — 54 comments in the full submission. View in context.
6.7k
c/trialwatch·submitted 2 years ago by u/rohan_steiner

week 16 check-in — 46kg down, early fullness manageable, one thing confusing me

Trial Databranch of 9 comments

Confession thread, sort of. I went from 1.0mg to 15mg much faster than I should have because the scale had stalled and I got impatient. The stall broke about 11 weeks later, at which point I had no way of knowing whether the dose increase did anything or whether it would have broken anyway. So now I have muscle…

Read the full submission and all 54 comments →

This branch

9 comments, started 2 years ago
u/renal_outcomes_rMOD190 points·2 years ago

Retitled to remove editorialising. Put the evidence in the body.

replysharereportpermalink
u/rohan_steinerOP-11 points·2 years ago

absolute risk reduction, not relative risk reduction, that is how you decide

replysharereportpermalink
u/hugo_norgaard1 point·2 years ago

number-needed-to-treat is the house dialect

replysharereportpermalink
u/marit_laurent1 point·2 years ago

This is correct. Discontinuation arms show the regain reality.

replysharereportpermalink
u/rania_salinas1 point·2 years ago

Not to be pedantic but SURMOUNT and STEP are being used interchangeably and they are not interchangeable in real life.

replysharereportpermalink
u/heart_rate_bump1 point·2 years ago

give the trial name, phase, n, and primary endpoint in the body

replysharereportpermalink
u/yannick_salinas1 point·2 years ago

Which trial and what was the primary endpoint?

replysharereportpermalink
u/nhs_waitlist_nUK1 point·2 years ago·edited

give the trial name, phase, n, and primary endpoint in the body

replysharereportpermalink
u/rohan_cardoso1 point·2 years ago

Strongly agree. Phase 2 is investigational, not conclusive.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →